| 证券代码 | NVET.O |
| 证券名称 | Nexvet Biopharma plc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-02-05 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 4000000 |
| 首发募资额(元) | 40,000,000.00 USD |
| 首发主承销商 | BofA Merrill Lynch,Cowen and Company, LLC |
| 货币单位 | USD |
| 公司名称 | Nexvet Biopharma public limited company |
| 注册地址 | 爱尔兰 |
| 办公地址 | Unit 5, Sragh Technology Park, Rahan Road, Tullamore, Co. Offaly, Ireland |
| 成立日期 | - |
| 董事会主席 | - |
| 公司属地 | Ireland 爱尔兰共和国 |
| 公司网址 | www.nexvet.com |
| 电话 | +353 5793-24522 |
| 传真 | - |
| 公司简介 | Nexvet Biopharma public limited company and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent many of the top-selling therapies on the market today. The Company’s platform technology, which it refers to as “PETization,” is an algorithmic approach that enables the Company to rapidly create monoclonal antibodies (“mAbs”) a type of biologic, that are designed to be recognized as “self” or “native” by an animal’s immune system, a property referred to as “100% species-specificity.” PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals, thereby reducing clinical risk and development cost. |